December 28, 1967

Dr. Charles E. Marshall
Associate Director of
Clinical Research
Winthrop Laboratories
90 Park Avenue
New York, New York 10016

Dear Dr. Marshall:

Enclosed is a draft copy of a proposed study of oxypertine. After reviewing the available literature and discussing the clinical data with Dr. Hollister, my associates and I would like to recommend an EEG study. It is our belief, that such a study will provide data not otherwise available, which may be most useful in identifying the target populations for this psychoactive compound.

The facilities at the New York Medical College will be available to undertake such a study about March 1, 1968. I also have the assurance of my associates at the University of Missouri who are willing to carry out parallel studies, when they are necessary.

In addition, we would like to consider a clinical study in the population of the Mental Health Clinic, as soon as we have determined the EEG profile and made some recommendations based upon that experience. In that study, we would like to carry out a procedure similar to that followed in the clinical evaluation of cyclazocine as an antidepressant.

I would be grateful for your comments. In the interim, please accept my best wishes for a Prosperous and Happy New Year.

Sincerely yours,

Max Fink, M.D.
Professor of Psychiatry

MF:kp